In contrast, five treatments with low dose anti-Fas antibody (2 μg animal−1), induced dispersed localized liver cell damage and promoted the number of large-sized liver cell adenomas and hepatocellular carcinomas. Here, FAS is linked to hepatocellular carcinoma.